Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
Davis AI | $5,500,000 | (May 8, 2026)
Balcony | $12,700,000 | (May 8, 2026)
Jetty | $2,000,000 | (May 8, 2026)
ParcelBio | $13,000,000 | (May 8, 2026)
Jesse & Ben's | $10,000,000 | (May 8, 2026)
SageOx | $15,000,000 | (May 8, 2026)
CodeWords | $9,000,000 | (May 8, 2026)
Ethos | $22,750,000 | (May 8, 2026)
illoca | $13,000,000 | (May 8, 2026)
Lithosquare | $25,000,000 | (May 8, 2026)
Jurisphere.ai | $2,200,000 | (May 8, 2026)
OpsMill | $14,000,000 | (May 8, 2026)